(NASDAQ: JANX) Janux Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 47.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.24%.
Janux Therapeutics's earnings in 2025 is -$101,895,000.On average, 19 Wall Street analysts forecast JANX's earnings for 2025 to be -$140,348,893, with the lowest JANX earnings forecast at -$188,034,074, and the highest JANX earnings forecast at -$124,415,739. On average, 18 Wall Street analysts forecast JANX's earnings for 2026 to be -$185,664,251, with the lowest JANX earnings forecast at -$324,196,680, and the highest JANX earnings forecast at -$118,100,219.
In 2027, JANX is forecast to generate -$229,554,105 in earnings, with the lowest earnings forecast at -$366,636,972 and the highest earnings forecast at -$173,676,793.